New to Neuro

Dr Tina Soulis – CEO of niche not-for-profit CRO, Neuroscience Trials Australia

Tina is currently CEO of Neuroscience Trials Australia and has over 25 years of experience in the pharma and biotech industry. She also trained as a medical researcher until she found her calling in the clinical trials space. One of Tina’s greatest successes she says, ‘has been the relaunch, growth and expansion of Neuroscience Trials MORE

Creating Australian jobs: The clinical trials sector continues to grow

Clinical research is a significant contributor to the Australian economy according to Dr Bronwyn Evans, Chair and Sue McLeman, CEO of MTP Connect in their recent report on the economic profile and competitive advantage of clinical trials in Australia. The report shows that total clinical trials expenditure in this country was approximately $1.1 billion in MORE

It’s the Australian advantage: Clinical Trial Networks

Australia is the destination of choice for commercially sponsored clinical trials because of the international standing of its investigators, its vibrant world-class basic science community and its infrastructure that efficiently translates new discoveries into viable treatments for intractable diseases. ‘Our reputation in medical research is backed by first rate publications and our performance in clinical MORE

Mary Hayek – passionate project manager

Mary Hayek has been part of Neuroscience Trials Australia (Neuro Trials) for over three years and has more than 10 years’ experience as a project manager in clinical trials.  She says being part of a not-for-profit CRO, especially one that is well-renowned, highly respected, and closely affiliated with the Florey Institute of Neuroscience and Mental MORE

3 key steps to improving clinical trial start-up times

Of the many factors involved in choosing a clinical trials provider, start-up times are pushing the top of the list. Clinical trials are complicated and highly regulated and these factors alone contribute to lengthy clinical trial commencement times. Like all complex processes, attention to other details can keep delays in start up to a minimum. MORE

Jessica Jia – a successful career in clinical trials

After working exclusively in clinical oncology, Jessica made the exciting decision to transition into neuroscience clinical research in early 2017. She is thrilled to be part of the Neuroscience Trials Australia (NTA) team and is ‘excited to play a role in the development of innovative treatments and to be part of ongoing research in the MORE

Australia’s strength in Phase Two and Three Clinical Trials

Australia has an enviable reputation for clinical trials, especially in the Asia-Pacific region. World-class medical practitioners backed by an internationally recognised basic science community make Australia the location of choice for clinical trials, especially in the growing field of studies in neuroscience.  ‘We also have the infrastructure that simplifies the passage of trials through the MORE

CTN and CTX schemes smooth the way for clinical trials in Australia

This blog will explore the role/ definition and introduction of the CTN and CTX schemes and how these schemes are shaping the clinical trials sector in Australia With clinical trials activity growing globally the pressure is on clinical trials providers to streamline their services. Clinical trials are a growth sector worldwide driven by our desire MORE

NTA at STROKE 2017 – Queenstown

Are you attending STROKE 2017 in Queenstown? Drop in and say hello to NTA at stand 4. The 27th Annual Scientific Meeting of the Stroke Society of Australasia will be held from 23 to 25 August 2017 in beautiful Queenstown, New Zealand. The conference theme “Path to Recovery” signals the commitment to achieving excellence in MORE